Page 51 - IMO-2-2

Innovative Medicines & Omics Alzheimer’s disease and clinical trials

37. Cheng S, Hou J, Zhang C, et al. Minocycline reduces 48. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression
neuroinflammation but does not ameliorate neuron loss in a of immune system-associated antigens by cells of the human
mouse model of neurodegeneration. Sci Rep. 2015;5:10535. central nervous system: Relationship to the pathology of
Alzheimer’s disease. Neurobiol Aging. 1988;9:339-349.
doi: 10.1038/srep10535
doi: 10.1016/s0197-4580(88)80079-4
38. Hosoki S, Hansra GK, Jayasena T, et al. Molecular biomarkers
for vascular cognitive impairment and dementia. Nat Rev 49. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the
Neurol. 2023;19:737-753. distribution and morphology of microglia in the normal
adult mouse brain. Neuroscience. 1990;39:151-170.
doi: 10.1038/s41582-023-00884-1
doi: 10.1016/0306-4522(90)90229-w
39. Bir SC, Khan MW, Javalkar V, Toledo EG, Kelley RE.
Emerging concepts in vascular dementia: A review. J Stroke 50. Stowe AM, Ireland SJ, Ortega SB, et al. Adaptive lymphocyte
Cerebrovasc Dis. 2021;30:105864. profiles correlate to brain Aβ burden in patients with mild
cognitive impairment. J Neuroinflammation. 2017;14:149.
doi: 10.1016/j.jstrokecerebrovasdis.2021.105864
doi: 10.1186/s12974-017-0910-x
40. Litke R, Garcharna LC, Jiwani S, Neugroschl J. Modifiable
+
risk factors in Alzheimer disease and related dementias: 51. Liu Y, He X, Li Y, Wang T. Cerebrospinal fluid CD4 T
A review. Clin Ther. 2021;43:953-965. lymphocyte-derived miRNA-let-7b can enhances the
diagnostic performance of Alzheimer’s disease biomarkers.
doi: 10.1016/j.clinthera.2021.05.006 Biochem Biophys Res Commun. 2018;495:1144-1150.
41. Wu KM, Zhang YR, Huang YY, Dong Q, Tan L, Yu JT. The doi: 10.1016/j.bbrc.2017.11.122
role of the immune system in Alzheimer’s disease. Ageing
Res Rev. 2021;70:101409. 52. Lueg G, Gross CC, Lohmann H, et al. Clinical relevance of
specific T-cell activation in the blood and cerebrospinal fluid
doi: 10.1016/j.arr.2021.101409 of patients with mild Alzheimer’s disease. Neurobiol Aging.
42. Tamburini B, Badami GD, La Manna MP, Shekarkar 2015;36:81-89.
Azgomi M, Caccamo N, Dieli F. Emerging roles of cells and doi: 10.1016/j.neurobiolaging.2014.08.008
molecules of innate immunity in Alzheimer’s disease. Int J
Mol Sci. 2023;24:11922. 53. Saresella M, Calabrese E, Marventano I, et al. Increased
activity of Th-17 and Th-9 lymphocytes and a skewing of the
doi: 10.3390/ijms241511922 post-thymic differentiation pathway are seen in Alzheimer’s
43. Femminella GD, Dani M, Wood M, et al. Microglial disease. Brain Behav Immun. 2011;25:539-547.
activation in early Alzheimer trajectory is associated with doi: 10.1016/j.bbi.2010.12.004
higher gray matter volume. Neurology. 2019;92:e1331-e1343.
54. Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J.
doi: 10.1212/WNL.0000000000007133 Alzheimer’s disease: Key insights from two decades of
44. Dani M, Wood M, Mizoguchi R, et al. Tau aggregation clinical trial failures. J Alzheimers Dis. 2022;87:83-100.
correlates with amyloid deposition in both mild cognitive doi: 10.3233/JAD-215699
impairment and Alzheimer’s disease subjects. J Alzheimers
Dis. 2019;70:455-465. 55. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease
drug-development pipeline: Few candidates, frequent
doi: 10.3233/JAD-181168 failures. Alzheimers Res Ther. 2014;6:37.
45. Hamelin L, Lagarde J, Dorothee G, et al. Early and doi: 10.1186/alzrt269
protective microglial activation in Alzheimer’s disease: rd
A prospective study using 18F-DPA-714 PET imaging. 56. Murphy MP, LeVine H 3 . Alzheimer’s disease and the
Brain. 2016;139:1252-1264. amyloid-beta peptide. J Alzheimers Dis. 2010;19:311-323.
doi: 10.3233/JAD-2010-1221
doi: 10.1093/brain/aww017
57. Kim J, Jeon H, Yun Kim H, Kim Y. Failure, success, and
46. Kreisl WC, Henter ID, Innis RB. Imaging translocator
protein as a biomarker of neuroinflammation in dementia. future direction of alzheimer drugs targeting amyloid-β
cascade: Pros and cons of chemical and biological modalities.
Adv Pharmacol. 2018;82:163-185.
Chembiochem. 2023;24:e202300328.
doi: 10.1016/bs.apha.2017.08.004
doi: 10.1002/cbic.202300328
47. Kreisl WC, Lyoo CH, Liow JS, et al. (11)C-PBR28 binding
to translocator protein increases with progression of 58. Lu J, Pan Q, Zhou J, Weng Y, et al. Pharmacokinetics,
distribution, and excretion of sodium oligomannate, a
Alzheimer’s disease. Neurobiol Aging. 2016;44:53-61.
recently approved anti-Alzheimer’s disease drug in China.
doi: 10.1016/j.neurobiolaging.2016.04.011 J Pharm Anal. 2022;12:145-155.

Volume 2 Issue 2 (2025) 45 doi: 10.36922/IMO025050007